FHIR IG Statistics: ValueSet/2.16.840.1.113762.1.4.1235.350
| Package | us.nlm.vsac |
| Resource Type | ValueSet |
| Id | 2.16.840.1.113762.1.4.1235.350 |
| FHIR Version | R4 |
| Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1235.350/expansion |
| URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.350 |
| Version | 20230808 |
| Status | active |
| Date | 2023-08-08T01:00:54-04:00 |
| Name | COVID19Vaccine_EventClinicalGrouping |
| Title | COVID19 Vaccine_Event Clinical Grouping |
| Realm | us |
| Authority | hl7 |
| Description | b.well created value set by Sr. Clinical Business Analyst for the COVID19 Vaccine_Event Clinical Grouping. |
| Purpose | (Clinical Focus: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.),(Data Element Scope: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.),(Inclusion Criteria: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.),(Exclusion Criteria: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.) |
Resources that use this resource
No resources found
Resources that this resource uses
| CodeSystem |
| cpt | Current Procedural Terminology (CPT®) |
| cvx | Vaccine Administered Code Set (CVX) |
| HCPCSReleaseCodeSets | Healthcare Common Procedure Coding System (HCPCS) level II alphanumeric codes |
| rxnorm | RxNorm |
Narrative
No narrative content found in resource
Source
{
"resourceType": "ValueSet",
"id": "2.16.840.1.113762.1.4.1235.350",
"meta": {
"versionId": "6",
"lastUpdated": "2023-12-21T17:43:03.000-05:00",
"profile": [
"http://hl7.org/fhir/StructureDefinition/shareablevalueset",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
]
},
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
"valueContactDetail": {
"name": "B.well Connected Health Author"
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
"valueDate": "2024-09-24"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
"valueDate": "2023-08-08"
}
],
"url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.350",
"identifier": [
{
"system": "urn:ietf:rfc:3986",
"value": "urn:oid:2.16.840.1.113762.1.4.1235.350"
}
],
"version": "20230808",
"name": "COVID19Vaccine_EventClinicalGrouping",
"title": "COVID19 Vaccine_Event Clinical Grouping",
"status": "active",
"date": "2023-08-08T01:00:54-04:00",
"publisher": "B.well Connected Health Steward",
"description": "b.well created value set by Sr. Clinical Business Analyst for the COVID19 Vaccine_Event Clinical Grouping.",
"jurisdiction": [
{
"coding": [
{
"system": "urn:iso:std:iso:3166",
"code": "US"
}
]
}
],
"purpose": "(Clinical Focus: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.),(Data Element Scope: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.),(Inclusion Criteria: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.),(Exclusion Criteria: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.)",
"compose": {
"include": [
{
"valueSet": [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.345"
]
},
{
"valueSet": [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.346"
]
},
{
"valueSet": [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.348"
]
},
{
"valueSet": [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.349"
]
}
]
},
"expansion": {
"identifier": "urn:uuid:64e1af0b-069f-4fbb-8966-8672c97cd7b5",
"timestamp": "2025-05-23T20:23:47-04:00",
"total": 34,
"contains": [
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "207",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "208",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "210",
"display": "SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "211",
"display": "SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL dose"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "212",
"display": "SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "213",
"display": "SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "217",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "218",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2mL dose, tris-sucrose formulation"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "219",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2mL dose, tris-sucrose formulation"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "221",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "227",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 50 mcg/0.5 mL dose"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "228",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 25 mcg/0.25 mL dose"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "229",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 50 mcg/0.5 mL or 25 mcg/0.25 mL dose"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "230",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "2468235",
"display": "SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML Injectable Suspension"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "2470234",
"display": "SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML Injectable Suspension"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "2479835",
"display": "SARS-COV-2 (COVID-19) vaccine, vector - Ad26 100000000000 UNT/ML Injectable Suspension"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "300",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "301",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "302",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "308",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 3 mcg/0.3 mL dose"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "309",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "310",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dose"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "311",
"display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "313",
"display": "SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL dose"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "502",
"display": "SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN)"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "506",
"display": "SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA), CanSino Biological Inc./Beijing Institute of Biotechnology"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "510",
"display": "SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm)"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "511",
"display": "SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac)"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "518",
"display": "SARS-COV-2 COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "519",
"display": "SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna"
},
{
"system": "http://hl7.org/fhir/sid/cvx",
"version": "20250502",
"code": "520",
"display": "SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product (Comirnaty Bivalent), Pfizer-BioNTech"
},
{
"system": "http://www.ama-assn.org/go/cpt",
"version": "2025",
"code": "91304",
"display": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use"
},
{
"system": "http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets",
"version": "2025",
"code": "91304",
"display": "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use"
}
]
}
}
FHIR